the Fundamental Research Funds for the Central Universities(3332019083);the National Natural Science Foundation of China(Nos.81673497,81903695);the CAMS Innovation Fund for Medical Sciences(No.2019-I2M-1–001);the National Science&Technology Major Project"Key New Drug Creation and Manufacturing Program",China(No.2019ZX09201001).
Chronic tissue injury with fibrosis results in the disruption of tissue architecture,organ dysfunction,and eventual organ failure.Therefore,the development of effective antifibrotic drugs is urgently required.IMB-S7 i...
Ministry of Science and Technology of the People's Republic of China for the National Science(Grant No.2012ZX09301002-001-013)
Bifendate, a synthetic anti-hepatitis drug, exhibits polycrystalline mode phenomena with 2polymorphs reported(forms A and B). Single crystals of the known crystalline form B and 3 new crystallosolvates involving bifen...
This work was supported by research grants from the National Natural Science Foundation of China (No 30672497), the China Medical Board of New York (grant No 01-755), and the Hunan Health Research Foundation of Traditional Chinese Medicine (grant No 204041).
Aim: To evaluate the potential drug-drug interactions between bifendate and cyclosporine, a substrate of CYP3A4, in relation to different CYP3A4*18B genotype groups. Methods: Eighteen unrelated healthy subjects (s...
Project supported by a grant from the Natural Science Foundation of Beijing City(№7022017).
Aim: To investigate the effects of bifendate on serum and hepatic lipids level in rabbits and mice. Methods: Animals were administered bifendate [powdered pill suspended in 0.5% sodium carboxymethylcellulose (CMC)...